Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial

PURPOSE: To analyze the safety and efficacy of orally administered metronomic capecitabine plus pyrotinib in HER2 positive metastatic breast cancer (MBC) patients, we conducted a prospective phase II study with a single-arm design. METHODS: HER2 positive patients received oral metronomic capecitabin...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Maiyue, Liu, Jiaxuan, Wang, Zijing, Ma, Fei, Wang, Jiayu, Zhang, Pin, Li, Qing, Yuan, Peng, Luo, Yang, Fan, Ying, Mo, Hongnan, Lan, Bo, Li, Qiao, Xu, Binghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520922/
https://www.ncbi.nlm.nih.gov/pubmed/37742492
http://dx.doi.org/10.1016/j.breast.2023.103581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520922/
https://www.ncbi.nlm.nih.gov/pubmed/37742492
http://dx.doi.org/10.1016/j.breast.2023.103581

Ejemplares similares